The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment

Psychiatry Research

Volumn 200, Issue 2-3, 2012, Pages 1047-1050

  Wang, Yingcheng ^a   Liu, Xiang ^a   Yu, Yue ^a   Han, Yuanyuan ^a   Wei, Jinxue ^a   Collier, David ^a,b   Li, Tao ^a,b   Ma, Xiaohong ^a  

^a SICHUAN UNIVERSITY   (China)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Depression; Dopamine; Treatment response

Indexed keywords

DOPAMINE 2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DOPAMINE 2 RECEPTOR GENE; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAMILTON SCALE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D2; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84872398838     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.06.024     Document Type: Article

References (17)

1. D'Haese J., Camu F., Dekeyzer P.J., D'Haenen H.A. Propofol and methohexitone anaesthesia: effects on the profile of mood state. European Journal of Anaesthesiology 1994, 11:359-363.
2. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Archives of General Psychiatry 2007, 64:327-337.
3. Ebert D., Feistel H., Loew T., Pirner A. Dopamine and depression-striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berlin) 1996, 126:91-94.
4. Entsuah A.R., Huang H., Thase M.E. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. Journal of Clinical Psychiatry 2001, 62:869-877.
5. Healy E., McKeon P. Dopaminergic sensitivity and prediction of antidepressant response. Journal of Psychopharmacology 2000, 14:152-156.
6. Huuhka K., Anttila S., Huuhka M., Hietala J., Huhtala H., Mononen N., Lehtimaki T., Leinonen E. Dopamine 2 receptor C957T and catechol-o-methyltransferase Val158Met polymorphisms are associated with treatment response in electroconvulsive therapy. Neuroscience Letters 2008, 448:79-83.
7. Kameda K., Kusumi I., Suzuki K., Miura J., Sasaki Y., Koyama T. Effects of citalopram on dopamine D2 receptor expression in the rat brain striatum. Journal of Molecular Neuroscience 2000, 14:77-86.
8. Kendler K.S., Gatz M., Gardner C.O., Pedersen N.L. A Swedish national twin study of lifetime major depression. American Journal of Psychiatry 2006, 163:109-114.
9. Klimek V., Schenck J.E., Han H., Stockmeier C.A., Ordway G.A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biologcal Psychiatry 2002, 52:740-748.
10. Montgomery S.A. The under-recognized role of dopamine in the treatment of major depressive disorder. International Clinical Psychopharmacology 2008, 23:63-69.
11. Nutt D.J. The role of dopamine and norepinephrine in depression and antidepressant treatment. Journal of Clinical Psychiatry 2006, 67(Suppl. 6):3-8.
12. Papp M., Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. European Journal of Pharmacology 1994, 263:1-7.
13. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackeim H.A., Kupfer D.J., Luther J., Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. American Journal of Psychiatry 2006, 163:1905-1917.
14. Shah P.J., Ogilvie A.D., Goodwin G.M., Ebmeier K.P. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychological Medicine 1997, 27:1247-1256.
15. Sullivan P.F., Neale M.C., Kendler K.S. Genetic epidemiology of major depression: review and meta-analysis. American Journal of Psychiatry 2000, 157:1552-1562.
16. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 2001, 178:234-241.
17. Thase M.E., Haight B.R., Richard N., Rockett C.B., Mitton M., Modell J.G., VanMeter S., Harriett A.E., Wang Y. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Journal of Clinical Psychiatry 2005, 66:974-981.